Document Detail

Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling.
MedLine Citation:
PMID:  22820509     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The trifunctional antibody ertumaxomab bivalently targets the human epidermal growth factor receptor 2 (Her2) on epithelial (tumor) cells and the T cell specific CD3 antigen, and its Fc region is selectively recognized by Fcγ type I/III receptor-positive immune cells. As a trifunctional immunoglobulin, ertumaxomab therefore not only targets Her2 on cancer cells, but also triggers immunological effector mechanisms mediated by T and accessory cells (e.g., macrophages, dendritic cells, natural killer cells). Whether molecular effects, however, might contribute to the cellular antitumor efficiency of ertumaxomab are largely unknown.
METHODS: Potential molecular effects of ertumaxomab on Her2-overexpressing BT474 and SK-BR-3 breast cancer cells were evaluated. The dissociation constant Kd of ertumaxomab was calculated from titration curves that were recorded by flow cytometry. Treatment-induced changes in Her2 homodimerization were determined by flow cytometric fluorescence resonance energy transfer measurements on a cell-by-cell basis. Potential activation / deactivation of Her2, ERK1/2, AKT and STAT3 were analyzed by western blotting, Immunochemistry and immunofluorescent cell staining.
RESULTS: The Kd of ertumaxomab for Her2-binding was determined at 265 nM and the ertumaxomab binding epitope was found to not overlap with that of the therapeutic anti-Her2 monoclonal antibodies trastuzumab and pertuzumab. Ertumaxomab caused an increase in Her2 phosphorylation at higher antibody concentrations, but changed neither the rate of Her2-homodimerization /-phosphorylation nor the activation state of key downstream signaling proteins analyzed.
CONCLUSIONS: The unique mode of action of ertumaxomab, which relies more on activation of immune-mediated mechanisms against tumor cells compared with currently available therapeutic antibodies for breast cancer treatment, suggests that modular or sequential treatment with the trifunctional bivalent antibody might complement the therapeutic activity of other anti-Her2/anti-ErbB receptor reagents.
Simone Diermeier-Daucher; Olaf Ortmann; Stefan Buchholz; Gero Brockhoff
Related Documents :
3978639 - Effect of tunicamycin on release of macromolecules and tumor antigens by human melanoma...
6688589 - Cell surface glycoproteins of 13762nf mammary adenocarcinoma clones of differing metast...
7844169 - Control of stable lamellipodia formation by expression of cell surface beta 1,4-galacto...
16325369 - The interaction between acanthamoeba polyphaga and human osteoblastic cells in vitro.
22912899 - Inhibition of pdgf-b induction and cell growth by syndecan-1 involves the ubiquitin and...
19018459 - In vitro and in vivo studies of osteoblast cell response to a titanium-6 aluminium-4 va...
23880269 - Conditioned medium from periapical follicle cells induces the odontogenic differentiati...
3494139 - T-lymphocyte subsets in primary lung cancer.
1710649 - Characterization of yellow fever virus proteins e and ns1 expressed in vero and spodopt...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-07-23
Journal Detail:
Title:  mAbs     Volume:  4     ISSN:  1942-0870     ISO Abbreviation:  MAbs     Publication Date:    2012 Sep-Oct
Date Detail:
Created Date:  2012-09-07     Completed Date:  2013-01-17     Revised Date:  2013-09-03    
Medline Journal Info:
Nlm Unique ID:  101479829     Medline TA:  MAbs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  614-22     Citation Subset:  IM    
Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Bispecific / immunology*,  metabolism,  pharmacology*
Antibodies, Monoclonal / immunology*,  metabolism,  pharmacology*
Breast Neoplasms / metabolism,  therapy
Cell Line, Tumor
Epithelial Cells / metabolism*
Receptor, erbB-2 / drug effects*,  metabolism
Signal Transduction*
Reg. No./Substance:
0/Antibodies, Bispecific; 0/Antibodies, Monoclonal; 0/ertumaxomab; EC, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  High-yield boron nitride nanosheets from 'chemical blowing': towards practical applications in polym...
Next Document:  G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is me...